22 min listen
Understanding the Current and Future Role of Oral SERDs (Selective Estrogen Receptor Degraders) in the Management of ER-Positive Metastatic Breast Can…
Understanding the Current and Future Role of Oral SERDs (Selective Estrogen Receptor Degraders) in the Management of ER-Positive Metastatic Breast Can…
ratings:
Length:
38 minutes
Released:
Mar 11, 2024
Format:
Podcast episode
Description
Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York City discusses available and emerging data with oral SERDs for patients with ER-positive metastatic breast cancer.
CME information and select publications here (https://www.researchtopractice.com/OncologyTodayOralSERDsmBC23).
CME information and select publications here (https://www.researchtopractice.com/OncologyTodayOralSERDsmBC23).
Released:
Mar 11, 2024
Format:
Podcast episode
Titles in the series (100)
Dr Tom Lynch on Adjuvant EGFR TKIs in Lung Cancer and COVID-19 in Seattle: Dr Tom Lynch comments on the current status of oncology research and data soon to be presented from a Phase III trial evaluating the EGFR TKI osimertinib as adjuvant therapy for patients with non-small cell lung cancer and EGFR tumor mutations. by Oncology Today with Dr Neil Love